A new experimental cancer treatment is generating significant excitement among oncologists after clinical trial results showed it can dramatically shrink tumors and, in some cases, eliminate them completely in patients with advanced disease who had exhausted other treatment options.
The treatment, known as amivantamab, was tested in an international study involving patients from 11 countries. Participants had cancers that had either spread or returned after previous therapies and were no longer responding to conventional treatments such as chemotherapy and immunotherapy. Researchers reported that the injectable drug produced remarkable responses, with visible improvements often appearing within weeks.
Among 102 patients with head and neck cancer enrolled in the study, tumors either shrank substantially or disappeared entirely in 43 cases. Twenty-eight patients experienced significant tumor reduction, while doctors found no remaining detectable tumors in 15 participants.
Cancer specialists described the findings as highly unusual for a patient group with very limited treatment options. Professor Kevin Harrington of the Institute of Cancer Research in London said the results were particularly striking because the participants had already developed resistance to both chemotherapy and immunotherapy.
